

Niki Karavitaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4643740/publications.pdf>

Version: 2024-02-01

106
papers

7,368
citations

81743

39
h-index

56606

83
g-index

162
all docs

162
docs citations

162
times ranked

5393
citing authors

#	ARTICLE	IF	CITATIONS
1	Opioids and pituitary function: expert opinion. Pituitary, 2022, 25, 52-63.	1.6	15
2	The diagnosis and management of Cushing's syndrome in pregnancy. Journal of Neuroendocrinology, 2022, 34, e13118.	1.2	25
3	Postradioiodine Graves' management: The PRAGMA study. Clinical Endocrinology, 2022, 97, 664-675.	1.2	3
4	Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. European Journal of Endocrinology, 2022, 186, P35-P52.	1.9	42
5	Cushing's syndrome update: 100 years after Minnie G. Journal of Neuroendocrinology, 2022, 34, .	1.2	17
6	Response to Letter to the Editor: "Prevention of Adrenal Crisis: Cortisol Response to Major Stress Compared to Stress Dose Hydrocortisone Delivery". Journal of Clinical Endocrinology and Metabolism, 2021, 106, e404-e406.	1.8	1
7	Mortality of Patients with Cushing's Disease. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 203-207.	0.6	11
8	Perioperative endocrinological management in patients with pituitary adenomas. , 2021, , 421-427.		2
9	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.1	31
10	Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations. European Journal of Endocrinology, 2021, 184, P1-P16.	1.9	32
11	Epidemiology and mortality of Cushing's syndrome. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101521.	2.2	45
12	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	5.5	315
13	Craniopharyngiomas. Presse Medicale, 2021, 50, 104078.	0.8	5
14	Response to Letter to the Editor from Chee et al: "Prevention of Adrenal Crisis: Cortisol Response to Major Stress Compared to Stress Dose Hydrocortisone Delivery". Journal of Clinical Endocrinology and Metabolism, 2021, 106, e407-e408.	1.8	0
15	Metastatic colon cancer in the pituitary: A case report with review of literature. Journal of Innovative Optical Health Sciences, 2021, 16, 872-875.	0.5	3
16	Opioids and Their Endocrine Effects: A Systematic Review and Meta-analysis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1020-1029.	1.8	66
17	Dopamine agonist resistant prolactinomas: any alternative medical treatment?. Pituitary, 2020, 23, 27-37.	1.6	44
18	Opioid-induced endocrinopathies. Lancet Diabetes and Endocrinology,the, 2020, 8, 68-80.	5.5	38

#	ARTICLE	IF	CITATIONS
19	Outcomes of Patients with Nelson's Syndrome after Primary Treatment: A Multicenter Study from 13 UK Pituitary Centers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1527-1537.	1.8	26
20	Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution. <i>Pituitary</i> , 2020, 23, 322-325.	1.6	34
21	Nelson's Syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 413-432.	1.2	14
22	The epidemiology of aggressive pituitary tumors (and its challenges). <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 209-212.	2.6	38
23	Prevention of Adrenal Crisis: Cortisol Responses to Major Stress Compared to Stress Dose Hydrocortisone Delivery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2262-2274.	1.8	68
24	Pituitary metastases: presentation and outcomes from a pituitary center over the last decade. <i>Pituitary</i> , 2020, 23, 258-265.	1.6	17
25	Histopathology of Parasellar Neoplasms. <i>Neuroendocrinology</i> , 2020, 110, 740-752.	1.2	6
26	Endocrinology in the time of COVID-19: Management of pituitary tumours. <i>European Journal of Endocrinology</i> , 2020, 183, G17-G23.	1.9	31
27	Pituitary Disorders: Striving for Excellence. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, xvii-xviii.	1.2	0
28	The Medical Therapy of Craniopharyngiomas: The Way Ahead. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5751-5764.	1.8	26
29	Hyperprolactinaemia. <i>Journal of Clinical Medicine</i> , 2019, 8, 2203.	1.0	66
30	Association of prolactin receptor (<i>PRLR</i>) variants with prolactinomas. <i>Human Molecular Genetics</i> , 2019, 28, 1023-1037.	1.4	24
31	Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a Pituitary Society survey. <i>Pituitary</i> , 2019, 22, 37-45.	1.6	24
32	MANAGEMENT OF ENDOCRINE DISEASE: Visual morbidity in patients with pituitary adenoma. <i>European Journal of Endocrinology</i> , 2019, 181, R185-R197.	1.9	20
33	Incidence, risk factors and clinical significance of postoperative haemodynamic instability after adrenalectomy for pheochromocytoma. <i>Gland Surgery</i> , 2019, 8, 729-739.	0.5	15
34	Non-functioning pituitary adenomas, not all the same and certainly not boring!. <i>Pituitary</i> , 2018, 21, 109-110.	1.6	4
35	Mortality in patients with non-functioning pituitary adenoma. <i>Pituitary</i> , 2018, 21, 203-207.	1.6	30
36	Males with prolactinoma are at increased risk of incident cardiovascular disease. <i>Clinical Endocrinology</i> , 2018, 88, 71-76.	1.2	22

#	ARTICLE	IF	CITATIONS
37	Recurrence in silent corticotroph adenomas after primary treatment: A systematic review and meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, , .	1.8	32
38	MECHANISMS OF ENDOCRINOLOGY: Endocrinology of opioids. <i>European Journal of Endocrinology</i> , 2018, 179, R183-R196.	1.9	46
39	The cortisol stress response induced by surgery: A systematic review and meta-analysis. <i>Clinical Endocrinology</i> , 2018, 89, 554-567.	1.2	107
40	Hypopituitarism, Causes, Diagnosis, Management and Mortality. , 2018, , 301-313.		0
41	Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. <i>Clinical Endocrinology</i> , 2018, 89, 346-353.	1.2	20
42	A rare challenging case of co-existent craniopharyngioma, acromegaly and squamous cell lung cancer. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.2	5
43	Macroprolactinoma causing VI, X, XII cranial nerve palsies nearly 30 years after initial treatment. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.2	0
44	Bilateral adrenal haemorrhage. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2017, 110, hcw212.	0.2	7
45	From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. <i>Endocrine-Related Cancer</i> , 2017, 24, C5-C8.	1.6	262
46	Outcome of Nonfunctioning Pituitary Adenomas That Regrow After Primary Treatment: A Study From Two Large UK Centers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1889-1897.	1.8	68
47	Prolactinomas diagnosed in the postmenopausal period: Clinical phenotype and outcomes. <i>Clinical Endocrinology</i> , 2017, 87, 508-514.	1.2	20
48	Diagnosis of pituitary disease. <i>Medicine</i> , 2017, 45, 464-469.	0.2	3
49	Epidemiology of acromegaly: review of population studies. <i>Pituitary</i> , 2017, 20, 4-9.	1.6	229
50	Recent advances in molecular pathology of craniopharyngioma. <i>F1000Research</i> , 2017, 6, 1202.	0.8	22
51	Clinical Diagnosis of Human ACP. , 2017, , 57-66.		1
52	Pheochromocytoma Is Characterized by Catecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, and Myocardial Dysfunction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2364-2374.	1.2	139
53	A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4189-4194.	1.8	27
54	Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3888-3921.	1.8	601

#	ARTICLE	IF	CITATIONS
55	Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 569-576.	5.5	151
56	THERAPY OF ENDOCRINE DISEASE: Surgery in microprolactinomas: effectiveness and risks based on contemporary literature. <i>European Journal of Endocrinology</i> , 2016, 175, R89-R96.	1.9	63
57	Mortality in patients with non-functioning pituitary adenoma is increased: systematic analysis of 546 cases with long follow-up. <i>European Journal of Endocrinology</i> , 2016, 174, 137-145.	1.9	51
58	Treating prolactinomas with dopamine agonists: always worth the gamble?. <i>Endocrine</i> , 2016, 51, 205-210.	1.1	46
59	A macroprolactinoma becoming resistant to cabergoline and developing atypical pathology. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, .	0.2	9
60	Pituitary disorders in pregnancy. <i>Hormones</i> , 2015, 14, 70-80.	0.9	21
61	Diabetes Insipidus after Traumatic Brain Injury. <i>Journal of Clinical Medicine</i> , 2015, 4, 1448-1462.	1.0	79
62	MANAGEMENT OF ENDOCRINE DISEASE: Pituitary tumour apoplexy. <i>European Journal of Endocrinology</i> , 2015, 172, R179-R190.	1.9	102
63	Neurofibromatosis Type 1 and pancreatic islet cell tumours: an association which should be recognized. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2015, 108, 573-576.	0.2	14
64	Efficacy and Complications of Pituitary Irradiation. <i>Endocrinology and Metabolism Clinics of North America</i> , 2015, 44, 117-126.	1.2	28
65	Clinical and biochemical manifestations of Cushing's disease. <i>Pituitary</i> , 2015, 18, 181-187.	1.6	19
66	Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4146-4154.	1.8	176
67	The Wnt Signalling Cascade and the Adherens Junction Complex in Craniopharyngioma Tumorigenesis. <i>Endocrine Pathology</i> , 2015, 26, 1-8.	5.2	29
68	Recent advances in the management of acromegaly. <i>F1000Research</i> , 2015, 4, 1426.	0.8	3
69	Cushing's Disease - Quality of Life, Recurrence and Long-term Morbidity. <i>European Endocrinology</i> , 2015, 11, 34.	0.8	6
70	Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab. <i>European Journal of Endocrinology</i> , 2014, 171, K1-K5.	1.9	45
71	Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas. <i>European Journal of Endocrinology</i> , 2014, 171, 705-710.	1.9	12
72	Management of craniopharyngiomas. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 219-228.	1.8	48

#	ARTICLE	IF	CITATIONS
73	A Patient with an Apparently Sporadic Pheochromocytoma with a Rearranged During Transfection Codon 635 Variant: A Mild Form of Multiple Endocrine Neoplasia Type 2?. <i>Endocrine Practice</i> , 2014, 20, e65-e68.	1.1	2
74	BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma. <i>Acta Neuropathologica</i> , 2014, 127, 927-929.	3.9	102
75	Rathke's cleft cyst. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 124, 255-269.	1.0	52
76	Diagnosis and management of prolactinomas and non-functioning pituitary adenomas. <i>BMJ</i> , The, 2014, 349, g5390-g5390.	3.0	35
77	Adrenal insufficiency in acute oral opiate therapy. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2014, 2014, 130071.	0.2	15
78	Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?. <i>Clinical Endocrinology</i> , 2013, 79, 217-223.	1.2	20
79	Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up. <i>European Journal of Endocrinology</i> , 2013, 169, 715-723.	1.9	119
80	Prevalence and incidence of pituitary adenomas. <i>Annales D'Endocrinologie</i> , 2012, 73, 79-80.	0.6	49
81	THERAPY IN ENDOCRINE DISEASE: Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review. <i>European Journal of Endocrinology</i> , 2012, 167, 137-143.	1.9	144
82	Can we ever stop imaging in surgically treated and radiotherapy-naïve patients with non-functioning pituitary adenoma?. <i>European Journal of Endocrinology</i> , 2011, 165, 739-744.	1.9	91
83	Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). <i>Journal of Endocrinology</i> , 2011, 169, 111-117.	1.2	930
84	Nelson's syndrome. <i>European Journal of Endocrinology</i> , 2010, 163, 495-507.	1.9	94
85	Opioid induced hypogonadism. <i>BMJ: British Medical Journal</i> , 2010, 341, c4462-c4462.	2.4	61
86	Radiation-induced hypopituitarism. <i>Endocrine-Related Cancer</i> , 2009, 16, 733-772.	1.6	72
87	Radiotherapy of other sellar lesions. <i>Pituitary</i> , 2009, 12, 23-29.	1.6	5
88	GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. <i>Clinical Endocrinology</i> , 2009, 70, 435-438.	1.2	47
89	The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly. <i>Clinical Endocrinology</i> , 2009, 71, 840-845.	1.2	15
90	Nonfunctioning pituitary adenomas: the Oxford experience. <i>Nature Reviews Endocrinology</i> , 2009, 5, 519-522.	4.3	32

#	ARTICLE	IF	CITATIONS
91	Non-adenomatous pituitary tumours. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 651-665.	2.2	31
92	Collision lesions of the sella: co-existence of craniopharyngioma with gonadotroph adenoma and of Rathke's cleft cyst with corticotroph adenoma. Pituitary, 2008, 11, 317-323.	1.6	65
93	Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clinical Endocrinology, 2008, 68, 970-975.	1.2	91
94	Craniopharyngiomas. Endocrinology and Metabolism Clinics of North America, 2008, 37, 173-193.	1.2	83
95	Craniopharyngiomas. Historical aspects of their management. Hormones, 2008, 7, 271-274.	0.9	13
96	Hypopituitarism Oddities: Craniopharyngiomas. Hormone Research in Paediatrics, 2007, 68, 151-153.	0.8	3
97	Silent corticotroph adenomas. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 1314-1318.	1.3	28
98	What is the natural history of nonoperated nonfunctioning pituitary adenomas?. Clinical Endocrinology, 2007, 67, 938-943.	1.2	157
99	Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clinical Endocrinology, 2006, 65, 524-529.	1.2	195
100	GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clinical Endocrinology, 2006, 64, 556-560.	1.2	108
101	Craniopharyngiomas. Endocrine Reviews, 2006, 27, 371-397.	8.9	460
102	The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clinical Endocrinology, 2005, 62, 282-288.	1.2	54
103	Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clinical Endocrinology, 2005, 62, 397-409.	1.2	540
104	Pegvisomant: a new treatment modality for acromegaly. Hormones, 2004, 3, 27-36.	0.9	3
105	Opioids and their endocrine effects: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 0, , .	1.8	0
106	Opioids and their endocrine effects: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 0, , .	1.8	0